Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Sunshine Biopharma (SBFM) over the last 8 years, with Q3 2025 value amounting to $462469.0.

  • Sunshine Biopharma's Accumulated Depreciation & Amortization changed N/A to $462469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $462469.0, marking a year-over-year change of. This contributed to the annual value of $336533.0 for FY2024, which is 7712.64% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Accumulated Depreciation & Amortization of $462469.0 as of Q3 2025.
  • Sunshine Biopharma's 5-year Accumulated Depreciation & Amortization high stood at $462469.0 for Q3 2025, and its period low was $12741.0 during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $336533.0 (2024), whereas its average is $258386.9.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first soared by 65506.1% in 2023, then soared by 7712.64% in 2024.
  • Sunshine Biopharma's Accumulated Depreciation & Amortization (Quarter) stood at $12741.0 in 2021, then surged by 97.5% to $25163.0 in 2022, then soared by 655.06% to $189996.0 in 2023, then surged by 77.13% to $336533.0 in 2024, then skyrocketed by 37.42% to $462469.0 in 2025.
  • Its Accumulated Depreciation & Amortization was $462469.0 in Q3 2025, compared to $412626.0 in Q2 2025 and $369180.0 in Q1 2025.